Home Cart Sign in  
Chemical Structure| 13408-09-8 Chemical Structure| 13408-09-8

Structure of 13408-09-8

Chemical Structure| 13408-09-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

β-Glycerophosphate disodium salt pentahydrate is a protein phosphatase inhibitor that acts as a phosphate group donor in matrix mineralization studies.

Synonyms: β-Glycerophosphate (sodium salt hydrate); β-Glycerophosphate sodium salt hydrate; Glycerol 2-Phosphate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of β-Glycerophosphate disodium salt pentahydrate

CAS No. :13408-09-8
Formula : C3H17Na2O11P
M.W : 306.11
SMILES Code : O=P([O-])([O-])OC(CO)CO.[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[Na+].[Na+]
Synonyms :
β-Glycerophosphate (sodium salt hydrate); β-Glycerophosphate sodium salt hydrate; Glycerol 2-Phosphate
MDL No. :MFCD00149083
InChI Key :PEMUISUYOHQFQH-UHFFFAOYSA-L
Pubchem ID :2735049

Safety of β-Glycerophosphate disodium salt pentahydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
β-Glycerophosphate disodium salt pentahydrate functions as an inhibitor of phosphatases[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
Mesenchymal stem cells 0.6 M and 1.0 M 21 days To test the effect of different concentrations of β-GPS on MSC differentiation, results showed 0.6 M β-GPS promoted neural cell differentiation, while 1.0 M β-GPS promoted adipocyte differentiation Bioact Mater. 2020 Jun 22;5(4):808-818.
Fibroblasts 1.0 M 14 days To test the effect of β-GPS on fibroblast proliferation and adhesion, results showed higher expression of proliferation and adhesion markers at 14 days compared to 7 days Bioact Mater. 2020 Jun 22;5(4):808-818.
C2C12 cells 10 mM 7 days To evaluate the effect of high phosphate concentration on the myogenic differentiation of C2C12 cells. Results showed that cells treated with BGP exhibited significantly lower expression of troponin T and maintained higher levels of Pax-7, indicating that BGP inhibited myogenic differentiation. J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1266-1279.
Mouse vascular smooth muscle cells (MOVAS) 10 mM 6 days To investigate the effect of β-GP on BK channel function in MOVAS cells. Results showed that β-GP-treated MOVAS cells were less sensitive to outward currents, indicating impaired BK channel function. Acta Pharmacol Sin. 2022 Mar;43(3):624-633.
Rat vascular smooth muscle cells 10 mM 7 days To investigate the effect of β-GP-induced calcification on the expression of BK channels in rat vascular smooth muscle cells. Results showed that β-GP-induced calcification decreased the expression of BK channels and α-SMA, while increasing the expression of Runx2. Acta Pharmacol Sin. 2022 Mar;43(3):624-633.
Mouse vascular smooth muscle cells (VSMC) 10 mM 7 days Induced VSMC calcification and observed increased pyroptosis and calcium deposition. Results showed that β-GP treatment significantly increased calcium deposition and the expression of pyroptosis-related proteins in VSMCs. Cell Death Dis. 2022 Mar 30;13(3):283.
Human Gingival Mesenchymal Stem Cells (HGMSCs) 10 mM 21 days Promote osteogenic differentiation of HGMSCs and increase the expression of autophagy markers Cell Commun Signal. 2019 Aug 19;17(1):98.
human aortic smooth muscle cells (HAoSMCs) 10 mM 12 days To investigate the effect of β-Glycerophosphate on osteogenic differentiation of HAoSMCs, results showed that OMD mRNA levels were significantly upregulated in osteogenic medium. Clin Transl Med. 2022 Feb;12(2):e682.
human mesenchymal stromal cell (hMSC)-derived chondrogenic pellets 10 mM 2 weeks Induction of in vitro cartilage mineralisation, resulting in loss of glycosaminoglycans, reduced expression of collagen II and X, and decreased VEGFA production. Cells. 2023 Apr 20;12(8):1202.
MDA-MB-231 human breast cancer cells 10 mM 14 days To investigate the effect of β-glycerophosphate on the mineralization of breast cancer cells, results showed that β-glycerophosphate-induced mineralization process was slower, beginning at day 11. Lab Invest. 2021 Sep;101(9):1267-1280.
MC3T3-E1 pre-osteoblasts 10 mM 28 days Induced osteogenic differentiation of MC3T3-E1 pre-osteoblasts, promoting the mineralization process. Cells. 2022 Aug 30;11(17):2702.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.27mL

0.65mL

0.33mL

16.33mL

3.27mL

1.63mL

32.67mL

6.53mL

3.27mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories